BSH 2018 | Polatuzumab vedotin and CAR T-cell therapy for diffuse large B-cell lymphoma

Graham Collins

There have been many promising therapies for lymphoma recently, with several interesting clinical trials in progress or upcoming. In this video, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, from Oxford University Hospitals NHS Foundation Trust, Oxford, UK, talks about the particularly interesting POLARIX study (NCT03274492), which is looking at polatuzumab vedotin combined with R-CHP versus R-CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). In another area, CAR T-cell therapy has been effective in treating multiple cancer types and Dr Collins outlines a trial comparing an autograft approach with a CAR T-cell approach for relapsed/refractory DLBCL, which could help make the case for CAR T-cell therapy to be utilized as standard practice by the NHS. This video was recorded at the British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK.

Share this video